This Human KLK15 overexpression lysate was created in HEK293 Cells and intented for use as a Western blot (WB) positive control. Purification of KLK15 protein (Cat: 12343-H08H) from the overexpression lysate was verified.
A DNA sequence encoding the human KLK15 (NP_059979.2) (Met1-Asn256) was expressed with a polyhistidine tag at the C-terminus.
The recombinant human KLK15 consists of 251 amino acids and predicts a molecular mass of 27.8 kDa.
Human KLK15 HEK293 Overexpression Lysate: 使用指南
Cell lysate was prepared by homogenization in ice-cold modified RIPA Lysis Buffer with cocktail of protease inhibitors (Sigma). Cell debris was removed by centrifugation. Protein concentration was determined by Bradford assay (Bio-Rad protein assay, Microplate Standard assay). The cell lysate was boiled for 5 min in 1 x SDS loading buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 5% b-mercaptoethanol, and lyophilized.
1. Centrifuge the tube for a few seconds and ensure the pellet at the bottom of the tube.
2. Re-dissolve the pellet using 200μL pure water and boil for 2-5 min.
3. Store the lyophilized cell lysate at 4℃. After re-dissolution, recommend to aliquot it into smaller quantities and store at -80℃.
1 X Sample Buffer (1 X modified RIPA buffer+1 X SDS loading buffer).
稳定性 & 储存条件
Store at 4℃ for up to twelve months from date of receipt. After re-dissolution, aliquot and store at -80℃ for up to twelve months. Avoid repeated freeze-thaw cycles.
Western Blot (WB) Optimal dilutions/concentrations should be determined by the end user.
Human KLK15 HEK293 Overexpression Lysate: 别称
Human ACO Overexpression Lysate; Human HSRNASPH Overexpression Lysate
KLK15 (Kallikrein Related Peptidase 15) is a Protein Coding gene. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Human KLK15 may have some utility as a prostate, ovarian, and breast cancer biomarker, based on previous studies, which examined mRNA levels of KLK15. Aberrant KLK15 expression is found in breast, ovarian, and prostate cancers. KLK15 over-expression is reported to be a significant predictor of reduced progression-free survival and overall survival in ovarian cancer. Kallikrein 15 (KLK15)/Prostinogen is a plausible candidate for prostate cancer susceptibility. Elevated KLK15 expression has been reported in prostate cancer and it has been described as an unfavorable prognostic marker for the disease.